⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682903 | 0.78 | — | — | |
| SCHEMBL2875149 | 0.72 | — | — | |
| SCHEMBL5553138 | 0.71 | TSHR (0.32) | — | |
| SCHEMBL5549399 | 0.67 | — | — | |
| SCHEMBL2551762 | 0.65 | — | — | |
| SCHEMBL18189690 | 0.65 | — | — | |
| SCHEMBL3260842 | 0.65 | — | — | |
| SCHEMBL16246127 | 0.65 | — | — | |
| SCHEMBL87668 | 0.65 | — | — | |
| SCHEMBL1485693 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029606-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-05-26 | — | — | EP | claimed |
| EP-2029606-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-03-04 | — | — | EP | claimed |
| US-7456167-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | claimed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| WO-2007140254-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | claimed |
| EP-1629864-A1 | Composition for dyeing keratin fibres comprising a methine direct dye with a benzoselenazolium group | L'OREAL (FR) | 2006-03-01 | — | — | EP | claimed |
| EP-0082023-A2 | Thienopyrimidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1983-06-22 | — | — | EP | claimed |
| EP-2029606-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2170831-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2029606-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009001968-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-31 | — | — | WO | disclosed |
| US-7456167-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007140254-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | disclosed |
| EP-1629864-A1 | Composition for dyeing keratin fibres comprising a methine direct dye with a benzoselenazolium group | L'OREAL (FR) | 2006-03-01 | — | — | EP | disclosed |
| EP-0082023-A2 | Thienopyrimidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1983-06-22 | — | — | EP | disclosed |
| US-3835131-A | 2-ACYL-5-NITROTHIAZOLE DERIVATIVES | SCHERING AG | 1974-09-10 | — | — | US | disclosed |